1. Hyaluronic acid-engineered NLCs as a macromolecular delivery platform for APOBEC3B siRNA and gemcitabine in triple-negative breast cancer: In vitro to in ovo assay
Quadir Ss, Tonge L, Ross K, Swadi R, Joshi G, Saleem I
Triple-negative breast cancer (TNBC) lacks targetable receptors and has poor clinical outcomes. This study combines hyaluronic acid (HA), a CD44-binding glycosaminoglycan, with APOBEC3B siRNA to engineer HA-functionalised nanostructured lipid carriers (HA-NLCs) that co-deliver gemcitabine hydrochloride (Gem HCl) and…
- APOBEC3B siRNA
- Breast cancer
- Chorioallantoic membrane (CAM) assay
- Gemcitabine hydrochloride
- Hyaluronic acid
- Nanostructured lipid carriers
